# 2026-03312: FDA Sets Clock for SYMVESS Patent Extension Review

2026-03312, Determination of Regulatory Review Period for Purposes of Patent Extension; SYMVESS, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-02-19, effective Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 20, 2026. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 18, 2026. See "Petitions" in the SUPPLEMENTARY INFORMATION section for more information. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-03312
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-03312
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; SYMVESS
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 8005
- Published: 2026-02-19
- Effective: Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 20, 2026. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 18, 2026. See "Petitions" in the SUPPLEMENTARY INFORMATION section for more information.
- Comments close: 2026-04-20
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Sets Clock for SYMVESS Patent Extension Review

## Summary

The FDA has set the official review period for SYMVESS, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind SYMVESS and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until April 20 or August 18, 2026, to speak up—potentially impacting patent length and market exclusivity.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMVESS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

## Effects PRIA read

- FDA sets SYMVESS review period: benefit, high. If you are the patent holder (Humacyte Global, Inc.), FDA has determined the regulatory review period for SYMVESS is 3,069 days total: 2,694 days in the testing phase and 375 days in the approval phase. FDA lists the key dates as an IND effective July 27, 2016, a BLA submission on December 11, 2023…
- Deadlines to challenge SYMVESS dates: mixed, low. Anyone who thinks the dates are wrong may ask FDA for a redetermination by April 20, 2026, and anyone may petition FDA about whether the applicant acted with due diligence by August 18, 2026. Petitions must follow FDA rules (21 CFR 60.24 and 21 CFR 60.30) and be filed electronically or by written s…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-03312 on federalregister.gov](https://www.federalregister.gov/documents/2026/02/19/2026-03312/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symvess)
- [2026-03312 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-02-19/pdf/2026-03312.pdf)

## Related
- [Previous: 2026-03311, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-03311)
- [Next: 2026-03313, Agency Information Collection Request. 60-Day Public Comment Request](https://policyrisk.com/federal-register/2026-03313)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-03312 (as of 2026-06-08).
